Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus
SBRT combined with sintilimab plus bevacizumab appears to improve treatment efficacy and demonstrates a favorable safety and feasibility profile for HCC with PVTT.
Authors
- Xubiao Wei
- Ye Lü (ORCID: https://orcid.org/0000-0002-2319-7681)
- Shuqun Cheng
- Y. J. Jiang (ORCID: https://orcid.org/0009-0003-4192-5253)
- Zihui Ma
- Xin L. Lu (ORCID: https://orcid.org/0000-0002-6612-8352)
- B J Zhou
- Xi Cheng
- Lei Wang
- Chongde Lu
Institutions
- Second Military Medical University (CN)
- Soochow University (CN)
- Second Affiliated Hospital of Soochow University (CN)
- Eastern Hepatobiliary Surgery Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-01-04
- DOI
- https://doi.org/10.1093/oncolo/oyaf439
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00